Radiopharmaceuticals Market Size, Share, and Industry Analysis, By Type (Actinium-225, Lutetium-177, Radium-223, Holmium-166, and Others), By Application (Oncology, Cardiology, and Others), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

RADIOPHARMACEUTICALS MARKET OVERVIEW

Global Radiopharmaceuticals Market size is projected to rise from USD 9.23 billion in 2025 to USD 9.98 billion in 2026, reaching around USD 20.11 billion by 2035, progressing at a CAGR of 8% between 2025 and 2035.

Radiopharmaceuticals are radioactive mixtures controlled to the patient, and checked by means of explicit imaging gadgets, for analysis and helpful purposes. It is made out of a radioisotope clinging to a natural particle. The natural particle passes the radioisotope on to explicit organs, tissues or cells. The radioisotope is chosen for its properties. They are utilized in the field of atomic medication as radioactive tracers in clinical imaging and in treatment for some illnesses (for instance, brachytherapy). Numerous pharmaceuticals use technetium-99m (Tc-99m) which has numerous valuable properties as a gamma-transmitting tracer nuclide.

Radio compound pharmaceuticals, or therapeutic radio compounds, are a gathering of drug drugs containing radioactive isotopes. They can be utilized as analytic and helpful specialists. They transmit radiation themselves, which is unique in relation to differentiate media which assimilate or adjust outer electromagnetism or ultrasound. Radiopharmacology is the part of pharmacology that works in these specialists. The fundamental gathering of these mixtures are the radiotracers used to analyze brokenness in body tissues. While not all clinical isotopes are radioactive, they are the most established yet most normal such medications. The different uses and benefits of it facilitates the growth of radiopharmaceuticals.

KEY FINDINGS

COVID-19 Impact: Need in Healthcare Industries to Improve Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with it experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden spike in CAGR is attributable to demand returning to pre-pandemic levels once the pandemic is over.

The unfavorable effect of the pandemic had given the execution of heavy lockdown rules across different nations, accomplishing aggravations in the import and flimsy activities of the thing. At any rate, the progression pursued for importance in the market extended the first class improvement during the pandemic.The usage of this in all the industries such as  healthcare sector for various drugs and others for purposes increased the necessity. With every one of the current circumstances additionally, the advancement of the market of radiopharmaceuticals figures post-COVID-19 is shown in the market.

LATEST TRENDS

Helping in Detecting Defects of Organs to Improve Market Growth

Only modest doses of radiopharmaceuticals are administered to patients in order to diagnose medical issues. The radiopharmaceutical then travels through or is absorbed by a body organ. The radiation is then detected and captured on camera using specialized imaging technology. With the use of these images, the nuclear medicine physician may examine how the organ is functioning and look for any cancer or tumors that might be there. The organs when detected with any defection can further be consulted with a radiologist. Such demands are expected to pose an opportunity for global  radiopharmaceuticals market growth during the forecast period.

• According to the International Atomic Energy Agency (IAEA), over 40 million nuclear medicine procedures are conducted annually worldwide, with radiopharmaceuticals driving most diagnostic imaging.

• The U.S. Food and Drug Administration (FDA) reported that 25% of new approvals in nuclear medicine in 2022 were radiopharmaceuticals, reflecting accelerated innovation in targeted therapies.

Request a Free sample to learn more about this report

RADIOPHARMACEUTICALS MARKET SEGMENTATION

• By Type

Based on type; the market is divided into actinium-225, lutetium-177, radium-223, holmium-166, and others.

Actinium-225 is the leading part in the type segment.

• By Application

Based on application; the market is divided into oncology, cardiology, and others.

Oncology is the leading part in the application segment.

DRIVING FACTORS

Helping in Treating Cancer to Increase Production

To treat specific types of cancer and other illnesses, some radio compounds are administered in higher doses. In some situations, the radioactive substance is absorbed by the malignant tissue and causes the tissue to die. The following information only pertains to pharmaceuticals when they are used sparingly to diagnose medical issues. Depending on the type of test, different patients will require varying doses of these when diagnosing medical issues. A radiopharmaceutical's radioactivity is measured in units called becquerels or curies. The doses of these are administered can be low or substantial. The radiation exposure from these dosages may be comparable to or even lower than the exposure from an x-ray examination of the same organ. Such demands are anticipated to drive the  radiopharmaceuticals market share.

• The World Health Organization (WHO) highlighted that cancer cases reached 19.3 million globally in 2020, with radiopharmaceuticals playing a key role in oncology diagnostics and treatment.

• According to the European Association of Nuclear Medicine (EANM), over 60% of radiopharmaceutical usage in Europe is in oncology, showing strong demand in cancer imaging and therapies.

Uses in Therapeutic Medication to Improve Market Growth

An in-vivo medication known as a radiopharmaceutical contains a radionuclide in the form of a simple salt or a complex. Since each radiopharmaceutical is designed to target certain tissues, binding sites, or biochemical pathways after administration, its chemical and physical identity and form are crucial. Depending on its unique physicochemical and radiation characteristics, a radiopharmaceutical can be employed for either therapeutic or diagnostic purposes. Radioactive decay is a property that makes radioisotopes valuable in medical applications, however different applications will benefit in different ways from radioactive emissions. In order to visualize and measure physiological functions, diagnose pathology, localize structures and pathways, and treat medical conditions, radioactive materials are frequently used. These factors and different  uses are anticipated to drive the  radiopharmaceuticals market growth during the forecast period.

RESTRAINING FACTORS

Health Reactions to Impede Market Growth

Many patients are concerned about the safety of nuclear medicine for their health. The procedures in this category include exposure to radiation, and there are hazards associated with that element, but because tracers employ such a small quantity, the potential benefits to the individual nearly always outweigh the potential risks. When utilizing tracers or receiving treatment, the majority of patients report experiencing headaches, dizziness, irregular heart rhythms, and a brief drop in blood pressure. Sometimes a rare allergic reaction can happen. These factors restrict the growth of the radiopharmaceuticals market. 

• The U.S. Nuclear Regulatory Commission (NRC) notes that nearly 35% of patients report mild side effects such as dizziness or irregular heartbeat during nuclear medicine procedures.

• According to Canada’s Nuclear Safety Commission, around 30% of hospitals face limited access to isotopes like Tc-99m, creating supply chain challenges for timely treatments.

• Request a Free sample to learn more about this report

•  

RADIOPHARMACEUTICALS MARKET REGIONAL INSIGHTS

North America to Dominate Market due to High Rate of Consumers

North America holds the biggest piece of the radiopharmaceuticals market because of the biggest assembling organizations in various conditions of nations such as the U.S. being the main makers. The accessibility of assets primarily relies upon the nations of America. The pace of utilization being higher in these districts is additionally one reason. This additionally added to the development in the foundation of different producer organizations to extend the market development in the area.

KEY INDUSTRY PLAYERS

New Methods by Manufacturers to Improve Market Growth

The report turns the overall relationship of get-together individuals and their new turn of events. Sorting out unequivocally exactly as expected to parties the essential data, it is utilized through basic assessment, creative developments, acquisitions, and interests. Discretionary viewpoints noted for this market join affiliations that work with and offer new things, the geographic locales they base on, computerization, lead gathering, making the most undeniably reimbursing pieces, and having guaranteed contact with their things.

• Bayer AG: According to company data, Bayer’s targeted therapies account for over 45% of radiopharmaceutical sales in prostate cancer treatments worldwide.

• GE Healthcare: As per the Society of Nuclear Medicine and Molecular Imaging (SNMMI), GE supplies nearly 30% of global medical imaging radiopharmaceuticals, supporting both PET and SPECT scans.

List Of Top Radiopharmaceuticals Companies

• Bracco Imaging (Italy)
• Bayer (U.S.)
• Mallinckrodt (Ireland)
• Nordion (Canada)
• Triad Isotopes (U.S.)
• Lantheus (U.S.)
• IBA Group (China)
• GE Healthcare (U.K.)
• China Isotope & Radiation (China)
• Jubilant Pharmacy (U.S.)
• Eli Lilly (U.S.)
• Advanced Accelerator Applications (France)
• SIEMENS (Germany)
• Dongcheng (China)
• Nvidia (U.S.)

REPORT COVERAGE

This examination outfits a report with evaluations that consider the portrayal liberated from the business ties that could change the timespan that is being tangled. The layout gives a reasonable perspective concerning collecting affiliations with its boundless appearance structures, market validness, and late new developments. By reviewing the parts, for example, division, expected open pieces, energy restores, plans, improvement, size, shares, drivers, blocks, and others, it gives a general assessment under the course of the finished point by point evaluation. This assessment could be changed considering the focal information and future market part changes.